ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
By E. Cutsem, A. Cervantes, René Adam, A. Sobrero, J. V. Krieken, D. Aderka, E. Aguilar, A. Bardelli, A. Benson, G. Bodoky and 37 more. Annals of Oncology, 2016
3,178 citations recorded by the source corpus.
Subfields: Hepatology, Oncology
View Paper: https://www.semanticscholar.org/paper/8260eb72df41dc392af49178f97a1cad728724cd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, neutral): “Metastatic rectal cancer stages are covered already in the ESMO consensus guidelines on metastatic colorectal cancer [13], but, in principle, should reflect the goals of treatment: tumour- and disease-related characteristics, patient-related factors (comorbidity, Surveillance and follow-up”
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. (2018, neutral): “3 (1-57) 10 (43) 9 (69) Pulmonary 6 (5) 1 (1) 10.”
- Colorectal cancer liver metastases – a population-based study on incidence, management and survival (2018, background): “The presence of unresectable extra-hepatic disease is still considered a contraindication to liver surgery [4].”
- Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017, background): “The most recent ESMO consensus guidelines [12] define tumour characteristics, patient characteristics and treatment characteristics as the drivers of decision-making in the first-line treatment setting, as well as therapeutic goal differentiating between ‘disease stabilization’ and the necessity for”
- Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. (2020, neutral): “White-cell count decrease 1 (1) 0 17 (12) 6 (4)”